LLY

1,009.85

-2.98%↓

JNJ

242.53

-0.92%↓

ABBV

221.21

-3.94%↓

NVS

164.89

-1.75%↓

MRK

119.17

-3.26%↓

LLY

1,009.85

-2.98%↓

JNJ

242.53

-0.92%↓

ABBV

221.21

-3.94%↓

NVS

164.89

-1.75%↓

MRK

119.17

-3.26%↓

LLY

1,009.85

-2.98%↓

JNJ

242.53

-0.92%↓

ABBV

221.21

-3.94%↓

NVS

164.89

-1.75%↓

MRK

119.17

-3.26%↓

LLY

1,009.85

-2.98%↓

JNJ

242.53

-0.92%↓

ABBV

221.21

-3.94%↓

NVS

164.89

-1.75%↓

MRK

119.17

-3.26%↓

LLY

1,009.85

-2.98%↓

JNJ

242.53

-0.92%↓

ABBV

221.21

-3.94%↓

NVS

164.89

-1.75%↓

MRK

119.17

-3.26%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

4.13 4.03

Buy Sell

Overview

Share price change

24h

Current

Min

3.95

Max

4.2

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+305.56% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-56M 199M
Previous open	0.1
Previous close	4.13

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 lut 2026, 23:25 UTC

Hot Stocks

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 lut 2026, 23:15 UTC

Earnings

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 lut 2026, 23:54 UTC

Market Talk

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 lut 2026, 23:47 UTC

Earnings

Ferrovial 4Q Net EUR197M >FER.MC

25 lut 2026, 23:45 UTC

Earnings

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 lut 2026, 23:42 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 lut 2026, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Company's Business Operations Remain Normal >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY EPS CNY47.67 >TCOM

25 lut 2026, 23:06 UTC

Earnings

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 lut 2026, 23:01 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 lut 2026, 23:00 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

25 lut 2026, 23:00 UTC

Market Talk

Earnings

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 lut 2026, 22:56 UTC

Market Talk

Earnings

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 lut 2026, 22:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 lut 2026, 22:40 UTC

Market Talk

Earnings

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 lut 2026, 22:40 UTC

Earnings

Karoon Energy Says Search for New CFO Well Advanced

25 lut 2026, 22:39 UTC

Earnings

Karoon Energy Says CFO Ray Church to Leave Company

25 lut 2026, 22:39 UTC

Earnings

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 lut 2026, 22:38 UTC

Earnings

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

305.56% upside

12 Months Forecast

Average 15.33 USD 305.56%

High 25 USD

Low 10 USD

Based on 3 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.